The speculative "gold rush" in healthcare artificial intelligence, characterised by a feverish pace of unbridled investment and a technology-first approach to product development, has concluded. A new, more discerning market has emerged, defined not by the promise of an algorithm but by a strategic fusion of technological efficacy, market access, and quantifiable value. This report provides a detailed analysis of this new equilibrium. The distinction between "thrivers" an